VanEck Biotech ETF
BBH
90 hedge funds and large institutions have $80.7M invested in VanEck Biotech ETF in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 30 reducing their positions, and 8 closing their positions.
1,239% more call options, than puts
Call options by funds: $6.36M | Put options by funds: $475K
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
20% more capital invested
Capital invested by funds: $67.4M → $80.7M (+$13.3M)
7% more funds holding
Funds holding: 84 → 90 (+6)
1.77% more ownership
Funds ownership: 17.86% → 19.62% (+1.8%)
50% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$3.23M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.34M |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$885K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$621K |
| 5 |
MJRIC
Mogy Joel R Investment Counsel
Beverly Hills,
California
|
+$310K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.92M |
| 2 |
Jane Street
New York
|
-$1.56M |
| 3 |
VF
Virtu Financial
New York
|
-$1.53M |
| 4 |
SFS
Strategic Financial Services
Utica,
New York
|
-$1.37M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.27M |
BBH Hedge Fund Activity: Q1 2019 in Review
90 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2019, worth a combined $80.7M — up 20% from $67.4M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new BBH positions and 8 closed out — a net gain of 6 holders — while 15 added to existing stakes and 30 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $3.23M. The largest seller was Royal Bank of Canada, cutting an estimated $1.92M.
- 90 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2019, up from 84 in Q4 2018.
- Funds reported $80.7M of VanEck Biotech ETF stock for Q1 2019, up 20% quarter-over-quarter.
- 14 funds opened new VanEck Biotech ETF positions in Q1 2019 and 8 closed out, a net change of +6 holders.
- The largest VanEck Biotech ETF buyer in Q1 2019 was Citadel Advisors, an estimated $3.23M added.
- The largest VanEck Biotech ETF seller in Q1 2019 was Royal Bank of Canada, an estimated $1.92M sold.
Based on aggregated 13F filings for Q1 2019.